---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-013520"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:21:00.999330+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aerovate Q1 net loss $10.9M; Phase 2b PAH trial topline data expected Q4 2023/Q1 2024

## Summary
- Net loss Q1 2022 $10.9M vs $2.8M in 2021; R&D up to $7.3M, G&A up to $3.8M.
- Cash and investments $161.1M; cash runway into second half of 2025.
- Site initiation delays push Phase 2b topline data from IMPAHCT trial to Q4 2023 or Q1 2024.
- Hired Marco Verwijs as SVP CMC and Susan Fischer as SVP Development Operations.
- Expanded IP portfolio with new U.S. patent and allowances.

## SEC filing metadata
- accession: 0001493152-22-013520
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000149315222013520/0001493152-22-013520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000149315222013520/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-013520
- JSON: https://secwatch.observer/filing/0001493152-22-013520.json
- Plain text: https://secwatch.observer/filing/0001493152-22-013520.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.